Trial Profile
A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Aug 2022
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary) ; OMO-1 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Octimet Oncology
- 08 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 19 May 2020 Planned End Date changed from 1 Oct 2021 to 1 Jun 2020.
- 19 May 2020 Planned primary completion date changed from 1 Aug 2021 to 1 May 2020.